Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators.

Segmental antigen bronchoprovocation was used to define the nature of the inflammatory process in allergic airway disease. Bronchoalveolar lavage fluid obtained from allergic rhinitis patients 12 min after segmental antigen instillation (immediate response) revealed a significant increase in histamine and tryptase, but no cellular response. Repeat segmental lavage 48 h later (late response) showed marked and significant increases in both low and normal density eosinophils as well as striking elevations of eosinophil granular protein levels (major basic protein, eosinophil-derived neurotoxin, eosinophil cationic protein, and eosinophil peroxidase). Leukotriene C4, but not tryptase, concentrations were also consistently elevated in late lavage samples. Further, the late lavage samples showed a significant increase in interleukin-5 concentrations that correlated with the presence of eosinophils and eosinophil granular proteins. Neither eosinophils nor soluble mediators of eosinophils increased when normal subjects were similarly challenged with antigen. These data suggest that eosinophils are attracted to the airway during the late-phase allergic reaction and that IL-5 may produce changes in airway eosinophil density and promote the release of granular proteins to cause airway injury.

[1]  R. Folkerth,et al.  Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[3]  G. Gleich,et al.  Epithelium-dependent contraction of airway smooth muscle caused by eosinophil MBP. , 1990, The American journal of physiology.

[4]  L. Schwartz,et al.  Immunologic and physicochemical evidence for conformational changes occurring on conversion of human mast cell tryptase from active tetramer to inactive monomer. Production of monoclonal antibodies recognizing active tryptase. , 1990, Journal of immunology.

[5]  W. Busse,et al.  The appearance of hypodense eosinophils during interleukin-2 treatment. , 1990, The Journal of allergy and clinical immunology.

[6]  J. Abrams,et al.  Host-reactive CD4+ and CD8+ T cell clones isolated from a human chimera produce IL-5, IL-2, IFN-gamma and granulocyte/macrophage-colony-stimulating factor but not IL-4. , 1990, Journal of immunology.

[7]  G. Gleich The eosinophil and bronchial asthma: current understanding. , 1990, The Journal of allergy and clinical immunology.

[8]  R. Rothlein,et al.  Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. , 1990, Science.

[9]  W. Owen,et al.  IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. , 1989, Journal of immunology.

[10]  S. Galli,et al.  Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines , 1989, The Journal of experimental medicine.

[11]  A. Sheffer,et al.  Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome , 1989, The Journal of experimental medicine.

[12]  K. Chung,et al.  Stimulation of degranulation from human eosinophils by platelet-activating factor. , 1989, Journal of immunology.

[13]  R. Kyle,et al.  IgA-induced eosinophil degranulation. , 1989, Journal of immunology.

[14]  A. Kay,et al.  The relationship between infiltrating CD4+ lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man. , 1988, Journal of immunology.

[15]  L. Schwartz,et al.  Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic response. , 1988, The Journal of allergy and clinical immunology.

[16]  S. Wenzel,et al.  Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. , 1988, The American review of respiratory disease.

[17]  C. J. Dunn,et al.  Development of a prolonged eosinophil-rich inflammatory leukocyte infiltration in the guinea-pig asthmatic response to ovalbumin inhalation. , 1988, The American review of respiratory disease.

[18]  J. Gamble,et al.  Recombinant human interleukin 5 is a selective activator of human eosinophil function , 1988, The Journal of experimental medicine.

[19]  H. S. Earl,et al.  Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. , 1987, The New England journal of medicine.

[20]  J. Cesbron,et al.  Role of specific IgE antibodies in peroxidase (EPO) release from human eosinophils. , 1986, Journal of immunology.

[21]  G. Gleich,et al.  The eosinophil and the pathophysiology of asthma. , 1986, The Journal of allergy and clinical immunology.

[22]  A. Togias,et al.  Inflammatory mediators in late antigen-induced rhinitis. , 1985, The New England journal of medicine.

[23]  H. Sluiter,et al.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.

[24]  J. Harley,et al.  Distinctive cationic proteins of the human eosinophil granule: major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin. , 1983, Journal of immunology.

[25]  R. Bowsher,et al.  Rat histamine N-methyltransferase. Quantification, tissue distribution, purification, and immunologic properties. , 1983, The Journal of biological chemistry.

[26]  G. Gleich,et al.  Elevated serum levels in human pregnancy of a molecule immunochemically similar to eosinophil granule major basic protein , 1983, The Journal of experimental medicine.

[27]  S. Spector,et al.  Standardization of bronchial inhalation challenge procedures. , 1975, The Journal of allergy and clinical immunology.